Key Metrics
9.3
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.001 - 0.005
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Q1
Genetics
SJR
- Q1 Genetics
- Q1 Biochemistry
- Q1 Drug Discovery
- Q1 Molecular Biology
- Q1 Molecular Medicine
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.19
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Topics Covered
- Oligonucleotide
- RNA interference
- RNA editing
- Guide RNA
- Exon
- Amyloid precursor protein
- Antisense oligonucleotides
- Minicircle dna
- Serum protein
- Duchenne muscular dystrophy
- Exon skipping
- DNA Aptamers
- Antisense RNA
- Amyloid angiopathy
- Type 2 diabetes
- Protein splicing
- G-quadruplex
- RNA Aptamers
- Ribosomal protein
Journal Specifications
| Overview | |
| Publisher | MARY ANN LIEBERT, INC |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Nucleic Acid Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Addressing the Challenges of Treating Patients with Heterozygous Gain of Function Mutations.
- 23 Sep 24
- Nucleic acid therapeutics
-
Full paper
An Evaluation of First-in-Human Studies for RNA Oligonucleotides
- 23 Sep 24
- Nucleic Acid Therapeutics
-
Full paper
Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells.
- 12 Sep 24
- Nucleic acid therapeutics
-
Full paper
Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy.
- 27 Aug 24
- Nucleic acid therapeutics
-
Full paper
Mass Spectrometry as a Quantitative Tool for SpCas9 sgRNA Quality Control.
- 23 Aug 24
- Nucleic acid therapeutics
-
Full paper
A Guide to Chemical Considerations for the Pre-Clinical Development of Oligonucleotides.
- 7 Aug 24
- Nucleic acid therapeutics
Scite analysis
Powered by scite_
577 articles received 11.3k citations see all
- 255 Supporting
- 10,929 Mentioning
- 17 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 0 Errata
- 0 Expression of Concern
FAQs
How long has Nucleic Acid Therapeutics been actively publishing?
Nucleic Acid Therapeutics has been in operation since 2011 till date.
What is the publishing frequency of Nucleic Acid Therapeutics ?
Nucleic Acid Therapeutics published with a Bi-monthly frequency.
How many articles did Nucleic Acid Therapeutics publish last years ?
In 2023, Nucleic Acid Therapeutics published 26 articles.
What is the eISSN & pISSN for Nucleic Acid Therapeutics ?
For Nucleic Acid Therapeutics,eISSN is 2159-3345 and pISSN is2159-3337.
What is Citescore for Nucleic Acid Therapeutics ?
Citescore for Nucleic Acid Therapeutics is 9.3.
What is SNIP score for Nucleic Acid Therapeutics ?
SNIP score for Nucleic Acid Therapeutics is 1.19.
What is the SJR for Nucleic Acid Therapeutics ?
SJR for Nucleic Acid Therapeutics is Q1.
Who is the publisher of Nucleic Acid Therapeutics ?
MARY ANN LIEBERT, INC is the publisher of Nucleic Acid Therapeutics.